Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577655 | 0.87 | S1PR1 (0.45) | DRD2DRD3DRD4LMNA | |
| SCHEMBL5577919 | 0.87 | MT-CO2 (0.52) | MT-CO2TP53CCR1TOP1CCR5 | |
| SCHEMBL5577376 | 0.87 | MAPK8 (0.43) | MT-CO2TP53NR3C1CCR1 | |
| SCHEMBL5577302 | 0.85 | MT-CO2 (0.48) | MT-CO2TOP1CCR5LMNA | |
| SCHEMBL5577730 | 0.84 | CCR1 (0.48) | DRD2DRD3GNRHRDRD4CCR1 | |
| SCHEMBL5577489 | 0.83 | MT-CO2 (0.48) | MT-CO2DRD2DRD3GNRHRTP53 | |
| SCHEMBL5577826 | 0.83 | MT-CO2 (0.49) | MT-CO2DRD2DRD3 | |
| SCHEMBL5577911 | 0.82 | MT-CO2 (0.45) | MT-CO2CCR1TOP1LMNA | |
| SCHEMBL5577671 | 0.82 | MT-CO2 (0.43) | MT-CO2DRD3SIGMAR1CCR1TOP1 | |
| SCHEMBL5577507 | 0.82 | MT-CO2 (0.50) | MT-CO2DRD2DRD3DRD4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MT-CO2 2047/4885DRD2 4468/4885DRD3 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.